📰 Wegovy Approved in Canada to Cut Heart Attack Risk
Health Canada approves Wegovy to support weight management and reduce cardiovascular risks in adults with obesity.
Health Canada has approved Novo Nordisk’s NVO 0.00%↑ semaglutide injection, Wegovy, as the first medication in the country to aid in chronic weight management while reducing the risk of non-fatal heart attacks in adults with cardiovascular disease and a body mass index (BMI) of 27 or higher.
This decision follows results from the extensive “SELECT trial”, involving 17,600 participants across 41 countries. The trial demonstrated that Wegovy significantly reduced major adverse cardiovascular events (MACE), including heart attacks and strokes, compared to a placebo.
Vince Lamanna, President of Novo Nordisk Canada, emphasized the importance of this approval: “We are committed to providing innovative therapies that address critical health challenges facing Canadians.”
Wegovy, already available in over ten countries, was initially approved in Canada in 2021 for obesity treatment. This new approval marks a significant advancement in managing cardiovascular risks linked to obesity.
For patients and healthcare providers, Wegovy represents a promising step in integrated care for weight management and heart health.
Source: Yahoo Finance, Reuters
Disclaimer:
The information and opinions provided in this article are for informational and educational purposes only and should not be considered as investment advice or a recommendation to buy, sell, or hold any financial product, security, or asset. The Future Investors does not provide personalized investment advice and is not a licensed financial advisor. Always do your own research before making any investment decisions and consult with a qualified financial professional before making any investment decisions. Please consult the general disclaimer for more details.